Novo Nordisk sales and marketing update

The German Institute for Quality and Efficiency in Health Care (IQWiG) said data from Novo Nordisk supporting Xultophy insulin degludec/liraglutide to treat Type II diabetes was unsuitable and that no hint of added benefit was found because the studies did not show a fair comparison. Novo Nordisk said IQWiG defined human insulin as the appropriate comparator but the company’s clinical trials primarily used insulin degludec. Novo Nordisk said it used indirect comparisons in its submission, which IQWiG did not accept. ...